Gradiant Bioconvergence has been producing more than 400 patient-derived organoids (PDOs) from lung, gastric, and colorectal cancer patients. Our PDO culture system is fully optimized for drug-screening.
Discovery of Novel Drug Target
Discovery of Novel Drug Target
Gradiant Bioconvergence’s PDOs are fully analyzed for genetic variations at whole-exome level.
We are open to collaborations that are to exploit the collective data generated from our PDOs.
Lung PDO A
EGFR T790M VAF : 12 %
Responsive to Osimertinib
Lung PDO B
EGFR T790M VAF : 44 %
Resistant to Osimertinib
Lung PDO C
EGFR T790M VAF : 0 %
Resistant to Osimertinib
Drug Screening for Immuno-oncology
Drug Screening for Immuno-oncology
Gradiant Bioconvergence has developed co-culture system growing PDOs along autologous T cells or cancer-associated fibroblasts (CAFs).
Gene–edited PDOs
Gene–edited PDOs
Gradiant Bioconvergence has been upgrading gene-editing protocols for PDOs, creating disease models, and conducting genome-wide reverse genetics by means of CRISPR/Cas9 system.
Innovation in 3D Cell Culture System
Innovation in 3D Cell Culture System
Gradiant Bioconvergence develops serum-free growth factors by de novo protein engineering and decellularized extracellular matrix (dECM) for 3D cell culture. Our growth factors can be provided with discounted price and we welcome any request willing to use our growth factors and dECMs.
